Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sarepta Therapeutics Inc SRPT

Healthcare Biotechnology
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy... see more

Recent & Breaking News (NDAQ:SRPT)

Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

GlobeNewswire February 14, 2019

Solid Biosciences Shares Crash After Data Release On Muscular Dystrophy Candidate

Benzinga.com  February 7, 2019

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 31, 2019

Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire January 14, 2019

Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy

GlobeNewswire January 2, 2019

Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2019

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 31, 2018

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

GlobeNewswire December 20, 2018

Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors

GlobeNewswire December 11, 2018

New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire December 7, 2018

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2018

Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock

GlobeNewswire November 8, 2018

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

GlobeNewswire November 7, 2018

Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference

GlobeNewswire November 2, 2018

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 31, 2018

Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire October 30, 2018

Sarepta, Lysogene Announce Exclusive License Agreement for LYS - SAF302, a Late- stage Gene Therapy for the Treatment of MPS IIIA; Grant of Option Rights to an Additional CNS Gene Therapy Candidate

Benzinga.com  October 26, 2018

Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments

GlobeNewswire October 24, 2018

Q3 Earnings Preview For Sarepta Therapeutics

Benzinga.com  October 24, 2018

Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018

GlobeNewswire October 18, 2018